IDAHO FALLS, Idaho, April 1, 2026 /PRNewswire/ -- Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) ("Radnostix" or the "Company"), a leading manufacturer of radioisotope-focused technologies for medical, industrial, and research applications, today announced its fiscal year 2025 financial results and corporate updates.

Fiscal 2025 Highlights

   -- Total revenue reached $13.07 million, the second-highest annual revenue 
      in Company history, reflecting healthy demand across core segments 
      despite targeted supply chain challenges. 
 
   -- Calibration & Reference Products segment achieved record growth, with 
      sales increasing 21% to $4.25 million, driven by new PET-focused products, 
      expanded international sales, and recovery from prior-year Co-57 isotope 
      shortages. 
 
   -- Theranostics Products segment generated $6.84 million in revenue, 
      second-highest ever for the segment, despite multiple isotope shortages 
      throughout the year. Our generic Sodium Iodide I-131 remains the only 
      U.S.-manufactured generic of its kind. 
 
   -- Cobalt Products segment delivered $1.75 million in revenue while 
      successfully completing a major processing hot cell refurbishment that is 
      expected to extend asset life by 15--20 years and reduce annual 
      radiological waste costs by approximately $150,000. We are the only 
      U.S.-based manufacturer of finished Cobalt-60 products. 
 
   -- Medical Devices segment showed strong momentum with $229,000 in revenue 
      from third-party products and key progress toward 2026 launches of the 
      EasyFill Automated Capsule System and RadVent products. 
 
   -- Positive operating cash flow of $620,000, underscoring disciplined cost 
      management and operational efficiency despite raw material challenges. 
 
   -- Completed construction and received initial NRC license amendment for a 
      dedicated Calibration & Reference Products manufacturing facility, 
      positioning the Company for significant capacity expansion and product 
      portfolio growth in 2026. 
 
   -- Executed mutual termination of the DUF6 asset sale agreement; Radnostix 
      regained full control of these strategic assets amid the global nuclear 
      energy boom and will evaluate development options, including potential 
      license amendments for expanded uranium-related activities. 

"2025 was a year of refinement for Radnostix, where we focused on internal improvements to, which we believe will set us up for long-term success. Despite isotope shortages and management decision to delay Q4 cobalt-60 projects to 2026, we delivered the second-highest revenue in our history while making substantial investments in our future. We completed critical facility upgrades, advancing our Medical Devices pipeline, and strengthening our position as a trusted domestic supplier of high-value radioisotope products." Said Shahe Bagerdjian, President and Chief Executive Officer, adding "Our Calibration & Reference Products segment posted healthy growth, and we successfully refurbished our cobalt-60 hot cells, securing long-term production capability and cost savings. The name change to Radnostix implemented in Q4 of 2025 reflects our sharpened focus on innovation in advanced radioisotope technologies."

"Looking ahead, we are excited about the anticipated 2026 commercial launches of EasyFill and RadVent, expanded international opportunities, and the strategic value of our retained DUF6 assets in today's booming nuclear market."

2026 Outlook

The Company enters 2026 with strong momentum and several key catalysts:

   -- Full commercial launch of the EasyFill Automated Capsule System (targeted 
      Q3 2026) and RadVent products. 
 
   -- Continued expansion of the Calibration & Reference Products facility and 
      product line. 
 
   -- Submitting a theranostics GMP API drug master file. 
 
   -- Strategic evaluation of the DUF6 assets to capitalize on renewed global 
      interest in uranium fuel cycle services. 
 
                    Twelve months ended - December 31 
                 2025          2024       $ Change   % Change 
             ------------  ------------  ----------  -------- 
Sale of 
 product     $13,070,336   $13,899,760   $(829,424)    -6 % 
Gross 
 profit        7,702,656     8,648,553    (945,897)   -11 % 
Total 
 Operating 
 Expense       8,658,843     8,641,652     17,191      0 % 
Operating 
 Profit 
 (Loss) 
 Before 
 Other Exp     (956,187)       6,901      (963,088)  -13956 % 
Other 
 Income 
 (Expense)      48,185         1,673       46,512     2780 % 
              -----------   -----------   --------- 
Net Income 
 (Loss)      $ (908,002)   $   8,574     $(916,576)  -10690 % 
              ===========   ===========   ========= 
Net income 
per common 
share -- 
basic:            --            -- 
Net income 
per common 
share -- 
diluted:          --            -- 
Weighted 
 avg. shares 
 outstanding 
 - basic      526,795,202   522,289,354 
Weighted 
 avg. shares 
 outstanding 
 - diluted    526,795,202   522,289,354 
 
 
 
                   Years ended December 31, 
                      2025          2024        $ Change    % Change 
                  ------------   -----------   -----------  -------- 
Net income 
 (loss)          $ (908,002)    $   8,574     $  (916,576)  -10690 % 
Interest 
 expense, net       262,653        206,293          56,360      27 % 
Provision for 
income taxes           --            --                 --        -- 
Depreciation 
 and 
 amortization       402,440        401,067           1,373       0 % 
   EBITDA          (242,909)       615,934       (858,843)    -139 % 
Non-cash 
 stock-based 
 compensation       117,822        199,420        (81,598)     -41 % 
Gain on 
 disposal of 
 property, 
 plant, and 
 equipment             --         (13,492)          13,492    -100 % 
NRC Enforcement 
 Matters (a)         45,213        233,852       (188,639)     -81 % 
Medical Devices 
 Buildout (b)        50,194        200,568       (150,374)     -75 % 
Public Markets 
 Related Non- 
 Recurring 
 Costs (c)           93,423          --             93,423        -- 
   Adjusted 
    EBITDA       $   63,743     $ 1,236,282   $(1,172,539)     -95 % 
                  ============   ===========   ===========  ======== 
 
 
 
(a) Represents costs for an NRC violation that occurred in 2022, including 
 legal expenses, costs for corrective actions, and NRC fines. 
(b) Represents legal work for intitial buildout of the Medical Devices 
 business segment. 
(c) Represents non-recurring legal and professional fees in connection with 
 discrete capital markets and compliance-oriented initiatives. 
 

About Radnostix (formerly International Isotopes Inc.): Radnostix, Inc. (formerly International Isotopes Inc.) (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope-focused products. Radnostix manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. Radnostix provides contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients. Radnostix manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards under its RadQual brand. For more information, visit www.radnostix.com.

Non-GAAP Financial Measures

This report contains financial measures that do not comply with U.S. generally accepted accounting principles ("GAAP"), such as EBITDA and Adjusted EBITDA. EBITDA is defined as net income plus interest, income taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA, adjusted to exclude items that are deemed to be unusual and non-recurring, and that we do not believe are indicative of the companies recurring operating performance, such as non-cash stock-based compensation, gain on disposal of assets, and costs associated with NRC enforcement matters and our medical devices buildout.

These non-GAAP financial measures are supplemental measures to our results of operations as reported under GAAP. Our management uses these measures to better analyze our financial results and business operations. In management's opinion, these non-GAAP measures are useful to investors and other users of our financial statements by providing greater transparency into the ongoing operating performance of the Company and its future outlook. Such measures should not be considered alternatives to net income or any other performance measures derived in accordance with GAAP. The Company's measurement of EBITDA and Adjusted EBITDA may not be comparable to similar measures of other companies as they are not performance measures calculated in accordance with GAAP.

See the tables above for reconciliations of GAAP to non-GAAP measures.

Radnostix, Inc. (formerly International Isotopes Inc.) Safe Harbor Statement:

Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to, statements regarding the Company's current expected financial impact from the termination of the APA, the estimated value of the DUF6 Plant and related assets, statements with respect to the Company's future growth expectations. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of Radnostix, Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange

(MORE TO FOLLOW) Dow Jones Newswires

April 01, 2026 11:06 ET (15:06 GMT)